Centivax

To us, it was always clear that luminary clinical design and execution was key to our mission of maximizing global impact of universal vaccines in the 21st century and beyond. Jerald’s decision to join #Centivax full time will dramatically accelerate our vaccine development with his depth of experience, knowledge of the industry, connections with government, industrial and academic partners.

Centivax's Chief Executive Officer, Jacob Glanville, said, "We are thrilled to announce BioCina as our Master Cell Bank manufacturing partner for the first phase of manufacturing our universal influenza vaccine. BioCina's exemplary expertise and track record in mRNA/LNP MCB, combined with their state-of-the-art facilities, aligns perfectly with Centivax's commitment to innovation and quality. This partnership enables us to leverage BioCina's expertise to ensure the highest standards of vaccine production. Together, we're taking a significant step forward in bringing our universal influenza vaccine to market, with the goal of providing broad, lasting protection against the disease on a global scale."

Happening November 8: QB3 is hosting a webinar featuring Jacob Glanville, a serial #entrepreneur, and computational immuno-engineer. He is the also the Founder and CEO of Centivax, and was previously the Co-Founder and CEO of Distributed Bio. If you're available to join from 1-2PM PT, register here: https://lnkd.in/gRc_5i_6

We are thrilled to announce our new Chief Medical Officer, Jerald Sadoff. To us, it was always clear that luminary clinical design and execution was key to our mission of maximizing global impact of universal vaccines in the 21st century and beyond. Jerald’s decision to join #Centivax full time will dramatically accelerate our vaccine development with his depth of experience, knowledge of the industry, connections with government, industrial and academic partners.